glp 1 egfr cut off GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease Routine care data and the
Description
Nonalcoholic fatty liver disease and type 2 diabetes: Pathophysiological mechanisms shared between the two faces of the same coin

doi: 10.1097/01.sla.0000197715.96762.68

Healthcare professionals have also been advised to closely monitor and report adverse drug reactions associated with GLP-1 therapies

Tan, Z., Scheetz, J

Not everyone gets nausea, but its one of the most reported early side effects
